Search and analyze individual stocks with comprehensive metrics
Mono Pharmacre Ltd
Fundamental Score
Mono Pharmacre Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of MONOPHARMA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (56.72%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
9 factors identified
Premium Valuation Risk (P/E: 44.60x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-99.13%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-23.94%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Elevated Debt Levels (D/E: 1.76)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Weak Interest Coverage (1.35x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High Debt-to-Equity Ratio
Observation: Elevated financial risk due to high leverage.
Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Mono Pharmacre Ltd
About MONOPHARMA
Company Details
MONOPHARMA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Mono Pharmacre Ltd (MONOPHARMA)?
As of 15 Jan 2026, 09:50 am IST, Mono Pharmacre Ltd (MONOPHARMA) is currently trading at ₹13.15. The stock has a market capitalization of ₹37.02 (Cr).
Is MONOPHARMA share price Overvalued or Undervalued?
MONOPHARMA is currently trading at a P/E ratio of 44.60x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Mono Pharmacre Ltd share price?
Key factors influencing MONOPHARMA's price include its quarterly earnings growth (Sales Growth: -23.94%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Mono Pharmacre Ltd a good stock for long-term investment?
Mono Pharmacre Ltd shows a 5-year Profit Growth of N/A% and an ROE of 10.42%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.76 before investing.
How does Mono Pharmacre Ltd compare with its industry peers?
Mono Pharmacre Ltd competes with major peers in the Pharmaceuticals. Investors should compare MONOPHARMA's P/E of 44.60x and ROE of 10.42% against the industry averages to determine its competitive standing.
What is the P/E ratio of MONOPHARMA and what does it mean?
MONOPHARMA has a P/E ratio of 44.60x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹45 for every ₹1 of annual earnings.
How is MONOPHARMA performing according to Bull Run's analysis?
MONOPHARMA has a Bull Run fundamental score of 11.8/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does MONOPHARMA belong to?
MONOPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Mono Pharmacre Ltd.
What is Return on Equity (ROE) and why is it important for MONOPHARMA?
MONOPHARMA has an ROE of 10.42%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Mono Pharmacre Ltd generates profits from shareholders' equity.
How is MONOPHARMA's debt-to-equity ratio and what does it indicate?
MONOPHARMA has a debt-to-equity ratio of 1.76, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is MONOPHARMA's dividend yield and is it a good dividend stock?
MONOPHARMA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has MONOPHARMA grown over the past 5 years?
MONOPHARMA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in MONOPHARMA and why does it matter?
Promoters hold 56.72% of MONOPHARMA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is MONOPHARMA's market capitalization category?
MONOPHARMA has a market capitalization of ₹37 crores, placing it in the Small-cap category.
How volatile is MONOPHARMA stock?
MONOPHARMA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for MONOPHARMA?
MONOPHARMA has a 52-week high of ₹N/A and low of ₹N/A.
What is MONOPHARMA's operating profit margin trend?
MONOPHARMA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is MONOPHARMA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -23.94% and YoY Profit Growth of -99.13%.
What is the institutional holding pattern in MONOPHARMA?
MONOPHARMA has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.